You can access any of the podium or poster presentations’ abstracts by searching for it below. For the 2026 FIP world congress in Montreal, presentations and summaries from invited speakers are available below, while abstracts are published in the Pharmacy Education Journal (PEJ) here.
Export this Abstract | Print this Abstract |
Add to my preferred Abstracts list |
My preferred Abstracts list (0) |
Back to Search
Safety and efficacy of sacubitril/valsartan in patient with heart failure
- At: Glasgow (Scotland) (2018)
- Type: Poster
- Poster code: POS-HPS-048
- By: RAY, Chin (Chang Gung Memorial Hospital, Linkou, Taiwan, Department of Pharmacy)
- Co-author(s): Chin-Ying Ray
Tzu-Cheng Tsai
Shin-Tarng Deng - Abstract:
Background
Patients with heart failure (HF) are at high risk for hospital readmission in the first 30 days following HF hospitalization and high mortality rate within 5 years.According to the PARADIGM-HF study, sacubitril/valsartan (Entresto) reduce cardiovascular risk by 20%. However, clinicians are still worried whether this medicine will cause.. The access to the whole abstract and if available the presentation file is available to FIP members and to congress participants of that specific congress.
Please login
Last update 23 September 2026